AstraZeneca has requested US authorisation for emergency use of its new treatment to prevent COVID-19 in people who have a lessened response to vaccines because of a weakened immune system.
AstraZeneca requests emergency authoritisation for drug that reduces risk of developing COVID symptoms by 77%